NCT03630094View on ClinicalTrials.gov

Plasma and Intrapulmonary Concentrations Study of WCK 5222

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2017

Primary Completion Date

June 30, 2017

Study Completion Date

July 30, 2017

Conditions
PHA1A
Interventions
DRUG

FEP-ZID

A total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen

Trial Locations (1)

85006

Pulmonary Associates, Phoenix

Sponsors

Lead Sponsor

Wockhardt
All Listed Sponsors
lead

Wockhardt

INDUSTRY

NCT03630094 - Plasma and Intrapulmonary Concentrations Study of WCK 5222 | Biotech Hunter | Biotech Hunter